PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34373541-0	2021	Targeted activity of the small molecule kinase inhibitor Pz-1 towards RET and TRK kinases.	Pz-1	57-61	ret proto-oncogene	Homo sapiens	70-73	
34373541-1	2021	We have recently described Pz-1, a benzimidazole-based type-2 RET and VEGFR2 inhibitor.	Pz-1	27-31	ret proto-oncogene	Homo sapiens	62-65	
34373541-3	2021	Pz-1 potently inhibited proliferation of human cancer cells carrying either RET- or TRKA oncoproteins (IC50 ~ 1 nM), with a negligible effect against RET- and TRKA-negative cells.	Pz-1	0-4	ret proto-oncogene	Homo sapiens	76-79	
34373541-6	2021	In xenograft models, orally administered Pz-1 almost completely inhibited RET- and TRKA-mutant tumours at 1-3 mg/kg/day but showed a reduced effect on RET/TRKA-negative cancer models.	Pz-1	41-45	ret proto-oncogene	Homo sapiens	74-77